To further evaluate the therapeutic potential of RTA-408 against neuroblastoma in vivo, we established a cell-derived xenograft (CDX) model in mice using MYCN-amplified cells (SK-N-DZ) and non-MYCN-amplified cells (SK-N-AS). This evidence concerns the gene MYCN and neuroblastoma.